Q2 2026 Novocure Ltd Earnings Call Transcript
Key Points
- NovoCure Ltd (NVCR) reported its strongest commercial quarter to date with record net revenues and active patients on therapy.
- The company saw an 11% year-over-year increase in active patients for Optune Geo, with significant growth in the U.S., Germany, Japan, and global markets.
- NovoCure Ltd (NVCR) successfully launched Optune PACS, receiving 418 prescriptions and having 285 patients on therapy by the end of the quarter.
- The company received a CE mark for Optune Pax for treating locally advanced pancreatic cancer in Europe, expanding its market reach.
- NovoCure Ltd (NVCR) achieved a positive adjusted EBITDA for the first time since 2024, indicating progress towards profitability.
- NovoCure Ltd (NVCR) reported a net loss of $16 million for the quarter, although this was an improvement from the previous year.
- The company faces challenges in contracting with hospitals in Japan for Optune Lua, which could slow market penetration.
- There is uncertainty regarding the long-term sustainability of growth in the pancreatic cancer segment, as the company needs to increase repeat prescriptions.
- NovoCure Ltd (NVCR) is not planning a registrational trial for TT Fields therapy with RAS inhibitors in metastatic pancreatic cancer, which may limit future market opportunities.
- The company is still working through reimbursement hurdles in Germany for Optune Pax, which could delay revenue realization.
Good morning, and thank you for joining us to review Novacure's second-quarter 2026 performance. I'm joined on the phone today by our Executive Chairman, Bill Doyle CEO, Frank Leonard Chief Innovation and Medical Officer, Ori Weinberg and CFO, Christophe Brockmann.
For your reference, slides accompanying this earnings release can be found on our website, www.novacure.com on the Investor Relations page under Quarterly Results.
Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law.
Where appropriate, we will refer to non-GAAP financial measures to evaluate
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
